Meningioma radiotherapy response: understanding gene clues and how to tailor treatment
Official title: Mechanistic and Functional Genomic Interrogation of Meningioma Radiotherapy Response Genes
Funded at University of California, San Francisco · NIH-11379985 · Data updated 2026-11-12
A short research project will study why some meningioma tumors respond differently to radiotherapy by looking at gene activity and how it affects treatment outcomes.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 1, 2025 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $241,089 |
| NIH project number | 5R21NS141756-02 |
| Project ID | NIH-11379985 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with meningioma, particularly those with WHO grade 1–3 tumors, who may receive radiotherapy.
✕Less likely to help
Patients whose tumors do not show the studied genomic patterns or who are not treated with radiotherapy may not benefit.
What this research studies
This project analyzes tumor samples from meningioma patients to identify gene patterns linked to radiotherapy response. It uses cutting-edge genomic tools to map chromatin accessibility, gene expression, and gene function, aiming to connect molecular signals with treatment success or failure. The goal is to help doctors predict who will benefit from radiotherapy and to guide the development of more effective, personalized treatments for meningioma patients.
Why it matters
Potential benefit: If successful, this work could improve risk stratification and guide personalized radiotherapy strategies for meningioma patients.
How similar studies have gone: Previous work has shown that gene expression biomarkers can improve risk stratification and predict radiotherapy benefit in meningiomas.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Raleigh, David R — University of California, San Francisco
- Study coordinator: Raleigh, David R
Related research
Other NIH-funded projects on the same topics.
-
Biomarker-based guidance to predict meningioma outcomes and radiotherapy response
A gene-based test is being developed to help predict how meningioma tumors will behave and how patients may respond to radiotherapy.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A computer program helps plan radiation therapy for cervical and head-and-neck cancer patients to make treatments faster and more accurate.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A United Kingdom study is testing AI software that helps plan radiotherapy for cervical and head-and-neck cancer patients to save time and reduce the workload for clinicians in low-resource settings.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A UK research team is testing an AI-based software to automatically outline cancer areas and plan radiation beams to speed up treatment for cervical and head-and-neck cancers in LMICs.
-
AI-Powered Radiotherapy Planning for Cervical and Head & Neck Cancer
A new AI tool helps plan radiation therapy for cervical and head-and-neck cancers to save time and reduce the need for specialized staff.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A UK study from University College London uses AI to plan radiotherapy for cervical and head-and-neck cancers to save time and reduce the need for specialized staff, aiming to help patients in LMICs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.